ABCB1 and cancer: Through CRISPR/Cas9 gene editing, we recently reported that 110α and 110β subunits of the phosphoinositide 3-kinase (PI3K) signaling pathway are potential targets for reversal of ABCB1/P-gp- and ABCG2/BCRP-mediated cancer MDR in a manner independent of AKT expression [2].